AAAAAA

   
Results: 1-9 |
Results: 9
A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural systemtumour syndrome family
Authors: Randerson-Moor, JA Harland, M Williams, S Cuthbert-Heavens, D Sheridan, E Aveyard, J Sibley, K Whitaker, L Knowles, M Bishop, JN Bishop, DT
Citation: Ja. Randerson-moor et al., A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural systemtumour syndrome family, HUM MOL GEN, 10(1), 2001, pp. 55-62
Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma
Authors: Sibley, K Cuthbert-Heavens, D Knowles, MA
Citation: K. Sibley et al., Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma, ONCOGENE, 20(6), 2001, pp. 686-691
Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours
Authors: Sibley, K Stern, P Knowles, MA
Citation: K. Sibley et al., Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours, ONCOGENE, 20(32), 2001, pp. 4416-4418
Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening
Authors: Menon, U Talaat, A Rosenthal, AN Macdonald, ND Jeyerajah, AR Skates, SJ Sibley, K Oram, DH Jacobs, IJ
Citation: U. Menon et al., Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening, BR J OBST G, 107(2), 2000, pp. 165-169
Redefining a critical region of LOH on 4p16.3 in bladder cancer
Authors: Sibley, K Bell, S Knowles, MA
Citation: K. Sibley et al., Redefining a critical region of LOH on 4p16.3 in bladder cancer, GENE CHROM, 29(4), 2000, pp. 378-379
Survival and progression of HIV disease in women attending GUM/HIV clinicsin Britain and Ireland
Authors: Stephenson, JM Griffioen, A Woronowski, H Phillips, AN Petruckevitch, A Keenlyside, R Johnson, AM Anderson, J Melville, R Jeffries, DJ Norman, J Barton, S Chard, S Sibley, K Mitchelmore, M Brettle, R Morris, S O'Dornen, P Russell, J Overington-Hickford, L O'Farrell, N Chappell, J Mulcahy, RF Moseley, J Lyons, F Welch, J Graham, D Fadojutimi, M Kitchen, V Wells, C Byrne, G Tobin, J Tucker, L Harindra, V Mercey, DE Allason-jones, E Campbell, L French, R Johnson, MA Reid, A Farmer, D Saint, N Olaitan, A Madge, S Forster, G Phillips, M Sampson, K Nayagam, A Edlin, J Bradbeer, C de Ruiter, A Hargreaves, L Doyle, C
Citation: Jm. Stephenson et al., Survival and progression of HIV disease in women attending GUM/HIV clinicsin Britain and Ireland, SEX TRANS I, 75(4), 1999, pp. 247-252
Screening for ovarian cancer: a pilot randomised controlled trial
Authors: Jacobs, IJ Skates, SJ MacDonald, N Menon, U Rosenthal, AN Davies, AP Woolas, R Jeyarajah, AR Sibley, K Lowe, DG Oram, DH
Citation: Ij. Jacobs et al., Screening for ovarian cancer: a pilot randomised controlled trial, LANCET, 353(9160), 1999, pp. 1207-1210
A comparison of national cancer registry and direct follow-up in the ascertainment of ovarian cancer
Authors: MacDonald, N Sibley, K Rosenthal, A Menon, U Jeyarajah, A Oram, D Jacobs, I
Citation: N. Macdonald et al., A comparison of national cancer registry and direct follow-up in the ascertainment of ovarian cancer, BR J CANC, 80(11), 1999, pp. 1826-1827
Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation
Authors: Menon, U Talaat, A Jeyarajah, AR Rosenthal, AN MacDonald, ND Skates, SJ Sibley, K Oram, DH Jacobs, IJ
Citation: U. Menon et al., Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation, BR J CANC, 80(10), 1999, pp. 1644-1647
Risultati: 1-9 |